6533b822fe1ef96bd127cc8f

RESEARCH PRODUCT

Semi-Mechanistic Pharmacokinetic Model to Guide the Dose Selection of Nimotuzumab in Patients with Autosomal Dominant Polycystic Kidney Disease

Mirjam N. TrameLeyanis Rodríguez-veraRaymed A. Bacallao-méndezNiurys De Castro-suárezAnaelys R. Maceo-sinabeleVictor Mangas-sanjuanMayra Ramos-suzarteJose M. DavalosGledys Reynaldo-fernández

subject

Oncologymedicine.medical_specialtyEGFRPopulationAutosomal dominant polycystic kidney diseasePharmaceutical SciencePhases of clinical researchlcsh:RS1-441030226 pharmacology & pharmacyArticlesemi-mechanistic pharmacokineticslcsh:Pharmacy and materia medica03 medical and health sciences0302 clinical medicinePharmacokineticsInternal medicinepopulation analysismedicinePolycystic kidney diseaseNimotuzumabEpidermal growth factor receptoreducationNONMEMeducation.field_of_studybiologyautosomal dominant polycystic kidney diseasebusiness.industrynimotuzumabmedicine.diseaseNONMEM030220 oncology & carcinogenesisbiology.proteinbusinessmedicine.drug

description

Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disease characterized by an overexpression of epidermal growth factor receptor (EGFR). Nimotuzumab is a recombinant humanized monoclonal antibody against human EGFR. The aim of this study was to develop a population pharmacokinetic model for nimotuzumab and to identify demographic and clinical predictive factors of the pharmacokinetic variability. The population pharmacokinetics (PopPK) of nimotuzumab was characterized using a nonlinear mixed-effect modeling approach with NONMEM&reg

yearjournalcountryeditionlanguage
2020-11-26Pharmaceutics
10.3390/pharmaceutics12121147https://www.mdpi.com/1999-4923/12/12/1147